---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269522"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:53:18.890860+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sana Q3 net loss $42.2M; shifts focus to type 1 diabetes and in vivo CAR T, suspends allogeneic CAR T

## Summary
- Q3 net loss $42.2M ($0.16/share); cash $153.1M; raised $115.8M in Q3, pro forma cash $170.5M.
- Prioritizing SC451 (type 1 diabetes) IND as early as 2026 and SG293 in vivo CAR T IND as early as 2027.
- Suspended allogeneic CAR T programs SC291 and SC262; NEJM published positive 12-week data for UP421 showing insulin production without immunosuppression.
- Non-GAAP operating cash burn $108M for 9 months; non-GAAP net loss $39M for Q3.

## SEC filing metadata
- accession: 0001193125-25-269522
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312525269522/0001193125-25-269522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312525269522/sana-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269522
- JSON: https://secwatch.observer/filing/0001193125-25-269522.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.